Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Conditions
- Carcinoma
- Non-Small-Cell Lung Cancer
- Adenocarcinoma
Interventions
- DRUG: Elemene plus first or third generation EGFR-TKIs
- DRUG: First or third generation EGFR-TKIs
Sponsor
Tian Xie
Collaborators